Holen Sie sich die Stockscreener-App
2.75
1.08%
-0.03
Schlusskurs vom Vortag:
$2.78
Offen:
$2.75
24-Stunden-Volumen:
333.16K
Relative Volume:
0.86
Marktkapitalisierung:
$134.99M
Einnahmen:
$226.63M
Nettoeinkommen (Verlust:
$15.38M
KGV:
-55.00
EPS:
-0.05
Netto-Cashflow:
$35.61M
1W Leistung:
-4.51%
1M Leistung:
-3.17%
6M Leistung:
-7.72%
1J Leistung:
-30.03%
1-Tages-Spanne:
$2.74
$2.89
1-Wochen-Bereich:
$2.72
$3.12
52-Wochen-Spanne:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Vergleichen Sie PBYI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
2.75 | 134.99M | 226.63M | 15.38M | 35.61M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Fmr LLC - Defense World
Charles Schwab Investment Management Inc. Sells 8,574 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by BNP Paribas Financial Markets - Defense World
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward - Seeking Alpha
Puma Biotechnology (NASDAQ:PBYI) Lowered to Buy Rating by StockNews.com - MarketBeat
HRMY: 3 Emerging Biotech Stocks Developing Breakthrough Therapies - StockNews.com
PBYIPUMA BIOTECHNOLOGY INC Latest Stock News & Market Updates - StockTitan
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian
Puma Biotechnology Grants 7,500-Share Inducement Award to New Employee - StockTitan
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Discovering Promising US Penny Stocks In November 2024 - Simply Wall St
Puma Biotechnology (NASDAQ:PBYI) Downgraded by StockNews.com to Buy - MarketBeat
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer - MSN
Puma commences Phase II trial of alisertib for breast cancer treatment - Clinical Trials Arena
Puma Biotech Launches Phase 2 Trial for Advanced Breast Cancer Treatment | PBYI Stock News - StockTitan
245,695 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Bought by Los Angeles Capital Management LLC - MarketBeat
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Puma Biotechnology reports robust Q3 growth - Investing.com
Earnings call: Puma Biotechnology reports robust Q3 growth By Investing.com - Investing.com UK
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Nasdaq
Puma Biotechnology Reports Strong Q3 2024 Growth - TipRanks
Puma Biotechnology Q3 2024 Earnings Preview - MSN
Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Puma Biotechnology Reports Third Quarter 2024 Financial Results - sharewise
Puma Biotech: Q3 Earnings Snapshot - San Francisco Chronicle
Puma Biotechnology Grants 5,625-Share Inducement Award to New Employee - StockTitan
Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com - MarketBeat
Puma Biotechnology (PBYI) Set to Announce Quarterly Earnings on Thursday - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ - The Bakersfield Californian
3 US Penny Stocks With Market Caps Under $700M - Simply Wall St
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - BioSpace
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
What is Zacks Research's Forecast for PBYI FY2026 Earnings? - MarketBeat
Equities Analysts Offer Predictions for PBYI Q3 Earnings - MarketBeat
With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well? - Yahoo Finance
Puma Biotechnology quickly drops after patents for Tagrisso ruled invalid - MSN
FY2025 EPS Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) Decreased by Zacks Research - MarketBeat
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):